NCT01548482 - Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Adult Solid NeoplasmLung Carcinoid TumorRecurrent Digestive System Neuroendocrine Tumor G1Recurrent Renal Cell CarcinomaRecurrent Uterine Corpus SarcomaStage III Renal Cell CancerStage IIIB Uterine SarcomaStage IIIC Uterine SarcomaStage IV Renal Cell CancerStage IVA Uterine SarcomaStage IVB Uterine Sarcoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Temsirolimus

Given IV

BIOLOGICAL

Trebananib

Given IV

Trial Locations (3)

V5Z 4E6

BCCA-Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH